



Interleukin-18 Engineered For Resistance to IL-18 Binding Protein (IL-18BP) and Half-Life Extension to Enhance Its Therapeutic Potential

Poster
4076

Mark Whitmore,¹ Kristiana Dreaden,¹ Pinar Gurel,¹ Joshua Heiber,¹ Robert G. Newman,¹ Su-Ping Pearson,¹
Chunhua Wang,¹ Yanchun Zhao,¹ and Jean Chamoun¹

¹Mural Oncology plc, 852 Winter Street, Waltham, MA 02451

Disclosures

Mark Whitmore: Mural Oncology: employee, stock; Alkermes, Inc.: stock

Kristiana Dreaden: Mural Oncology: employee, stock; Alkermes, Inc.: stock

Pinar Gurel: Mural Oncology: employee, stock, patent; Alkermes, Inc.: stock, patent

Joshua Heiber: Mural Oncology: employee, stock, travel, patent; Alkermes, Inc.: stock

Robert G. Newman: Mural Oncology: employee, stock; Alkermes, Inc.: stock

Su-Ping Pearson: Mural Oncology: employee, stock

Chunhua Wang: Mural Oncology: employee, stock; Alkermes, Inc.: stock

Yanchun Zhao: Mural Oncology: employee, stock; Alkermes, Inc.: stock

Jean Chamoun: Mural Oncology: employee, stock, stock option, patent; Alkermes, Inc.: stock, stock option, patent